Dyadic announces development of COVID-19 Vaccine in India
May 26 2021 - 8:30AM
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ:
DYAI) a global biotechnology company focused on further improving,
applying and deploying its proprietary C1-cell protein production
platform to accelerate development, lower production costs and
improve the performance of biologic vaccines and drugs at flexible
commercial scales, today announced that the Company has entered
into a collaboration with Syngene International Limited
(“Syngene”), an integrated research, development, and manufacturing
services company, to develop a COVID-19 vaccine candidate that can
protect against the emerging variants of concern and which can be
manufactured affordably, at very large scale, using Dyadic’s
proprietary C1-cell protein production platform.
Like the expanded partnership previously
announced with Medytox, Inc., to co-develop vaccines in the
Republic of Korea and multiple Southeast Asian countries, Dyadic
will work with Syngene to develop a vaccine candidate to immunize
people against current and future variants of the COVID-19
virus.
Mahesh Bhalgat, COO, Syngene International
stated, “We look forward to our collaboration with Dyadic to
initially explore the development of a COVID-19 vaccine, and to
further evaluate the potential of developing a differentiated
vaccine platform based on Dyadic’s proprietary C1- cell line.”
Mark Emalfarb, Dyadic’s Founder and Chief
Executive Officer, commented, “We will work with Syngene to further
develop our proprietary and patented C-1 cell protein production
platform for its use in developing and manufacturing safe and
effective vaccines. If successful, such vaccines can be
manufactured rapidly and affordably, in very large quantities. The
global pandemic has only amplified the urgent need for vaccines.
With Syngene, we believe we have the right partner to develop and
produce a safe and effective vaccine candidate, in the quantities
the world will need at an affordable price. As we demonstrated
through our efforts with the Zoonosis Anticipation Preparedness
Initiative (ZAPI) and with the Israel Institute for Biological
Research (IIBR), our C1 gene expression platform may facilitate
faster, more durable, and more affordable responses to emerging
infectious diseases. To this end, our collaboration with Syngene is
an appropriate follow-up to our partnership with Medytox in Korea
and Southeast Asia, and we continue to explore similar arrangements
in other geographies to help bring high volume, low-cost, next
generation vaccine and drug manufacturing to parts of the world
that need these resources most urgently.”
About Syngene
Syngene International Ltd. (BSE: 539268, NSE:
SYNGENE, ISIN: INE398R01022) is an integrated research, development
and manufacturing services company serving the global
pharmaceutical, biotechnology, nutrition, animal health, consumer
goods and specialty chemical sectors. Syngene's more than 4700
scientists offer both skills and the capacity to deliver great
science, robust data management and IP security and quality
manufacturing at speed, to improve time-to-market and lower the
cost of innovation. With a combination of dedicated research
facilities for Amgen, Baxter, Bristol-Myers Squibb and Herbalife,
as well as 2 Mn sq. ft of specialist discovery, development and
manufacturing facilities, Syngene works with biotech companies
pursuing leading-edge science as well as multinationals including
GSK and Merck KGaA. For more details, visit
www.syngeneintl.com.
About Dyadic International,
Inc.
Dyadic International, Inc. is a global
biotechnology company which is developing what it believes will be
a potentially significant biopharmaceutical gene expression
platform based on the fungus Thermothelomyces heterothallica
(formerly Myceliophthora thermophila), named C1. The C1
microorganism, which enables the development and large-scale
manufacture of low-cost proteins, has the potential to be further
developed into a safe and efficient expression system that may help
speed up the development, lower production costs and improve the
performance of biologic vaccines and drugs at flexible commercial
scales. Dyadic is using the C1 technology and other technologies to
conduct research, development and commercial activities for the
development and manufacturing of human and animal vaccines and
drugs, such as virus like particles (VLPs) and antigens, monoclonal
antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars
and/or biobetters, and other therapeutic proteins. Certain other
research activities are ongoing which include the exploration of
using C1 to develop and produce certain metabolites and other
biologic products. Dyadic pursues research and development
collaborations, licensing arrangements and other commercial
opportunities with its partners and collaborators to leverage the
value and benefits of these technologies in development and
manufacture of biopharmaceuticals. As the aging population grows in
developed and undeveloped countries, Dyadic believes the C1
technology may help bring biologic vaccines, drugs, and other
biologic products to market faster, in greater volumes, at lower
cost, and with new properties to drug developers and manufacturers,
and improve access and cost to patients and the healthcare system,
but most importantly save lives.
Please visit Dyadic's website at
http://www.dyadic.com for additional information, including details
regarding Dyadic's plans for its biopharmaceutical business.
Contact:
Dyadic International, Inc.Ping W. RawsonChief Financial
OfficerPhone: (561) 743-8333Email: prawson@dyadic.com
SOURCE: Dyadic International, Inc.
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Sep 2023 to Sep 2024